Christian Renaudin

PhotoniCare was founded out of a shared passion to develop a superior solution for middle ear issues, primarily in children. With $10 billion spent annually to manage ear infections, and a documented 50% misdiagnosis rate for primary care physicians, current tools used to diagnose fluid in the middle ear fail to reliably interpret the patient’s condition. The FDA-cleared OtoSight™ Middle Ear Scope by PhotoniCare is a clinical diagnostic tool designed to eliminate subjectivity and speculation with a non-invasive and comprehensive assessment of middle ear fluid. OtoSight™ is indicated to not only visualize the presence of fluid, but also the fluid’s density, even in the presence of earwax. As a result, the simple-to-use OtoSight™ Middle Ear Scope has a 90+% reader accuracy in determining the presence or absence of fluid in the middle ear. Clinicians that have had an opportunity to use OtoSight™ consider it a game-changer. This is further demonstrated by multiple best-in-show product awards and over 20 supporting clinical publications. With OtoSight™, PhotoniCare makes the otherwise invisible visible while effectively informing a successful treatment plan like never before. Learn more at www.photoni.care.

PhotoniCare was founded out of a shared passion to develop a superior solution for middle ear issues, primarily in children. With $10 billion spent annually to manage ear infections, and a documented 50% misdiagnosis rate for primary care physicians, current tools used to diagnose fluid in the middle ear fail to reliably interpret the patient’s condition. The FDA-cleared OtoSight™ Middle Ear Scope by PhotoniCare is a clinical diagnostic tool designed to eliminate subjectivity and speculation with a non-invasive and comprehensive assessment of middle ear fluid. OtoSight™ is indicated to not only visualize the presence of fluid, but also the fluid’s density, even in the presence of earwax. As a result, the simple-to-use OtoSight™ Middle Ear Scope has a 90+% reader accuracy in determining the presence or absence of fluid in the middle ear. Clinicians that have had an opportunity to use OtoSight™ consider it a game-changer. This is further demonstrated by multiple best-in-show product awards and over 20 supporting clinical publications. With OtoSight™, PhotoniCare makes the otherwise invisible visible while effectively informing a successful treatment plan like never before. Learn more at www.photoni.care.

MEDFORCE ACCELERATOR LLC is a company based out of 502 MACE BLVD #15, DAVIS, California, United States.

Founded in 1995, The MarkeTech Group (TMTG) is a global medical-technology marketing consulting firm exclusively dedicated to the Healthcare and Medical Technology industries. Offering a comprehensive range of qualitative and quantitative market research services at any stage of product development including pre-launch through post launch monitoring, the company delivers tactical and strategic recommendations based on customized studies tailored to address specific client needs and objectives. With offices in the U.S., France, Brazil and partners in China, Japan, Canada, Mexico, Australia, India and the Middle East – TMTG’s multicultural staff and affiliates are able to provide clients effective strategic business decision making solutions based on its deep knowledge and insight of local worldwide business markets. This unique expertise in the industry enables TMTG to produce reliable recommendations that allow its clients to make critical business decisions quickly and confidently. Questions TMTG answers: Technology Assessment, Customer and Product Requirements, Opportunity Analysis, Segmentation Analysis, Product Concept Testing, Pricing, Branding, Product Positioning, Go to Market Planning, Post Launch Acceptance, Customer Satisfaction and Loyalty. Markets TMTG serves: Healthcare Industry, Medical Imaging, Device & Diagnostics, Healthcare IT, Pharmaceuticals and Biotechnology.